Indications
Therapeutic Asset Ratings
18,153 results matching 1 filter
91,564
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Cyclophosphamide
Cutaneous Melanoma
East Metropolitan Health Service, Australia
P3
BB
(66)
Cyclophosphamide
Chronic Progressive Multiple Sclerosis
Bruce Cree
P3
BB
(66)
Cyclophosphamide
Primary Peritoneal Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
P3
BB
(66)
Cyclophosphamide
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Nathan Denlinger
P3
BB
(66)
Cyclophosphamide
Richter Transformation
SWOG Cancer Research Network
P3
BB
(66)
Cyclophosphamide
Renal Cell Carcinoma
City of Hope Medical Center
P3
BB
(66)
Cyclophosphamide
Splenic Marginal Zone Lymphoma
SWOG Cancer Research Network
P3
BB
(66)
Cyclophosphamide
Gastric Neoplasm
National Cancer Institute (NCI)
P3
BB
(66)
Cytarabine
Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication
First Affiliated Hospital of Zhejiang University
P3
BB
(66)
Cytarabine
T-Cell Adult Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
P3
BB
(66)
Cytarabine
T Lymphoblastic Leukemia/Lymphoma
Princess Maxima Center for Pediatric Oncology
P3
BB
(66)
Cytarabine
T-Cell Non-Hodgkin Lymphoma
St. Jude Children's Research Hospital
P3
BB
(66)
Cytarabine
Myeloproliferative Neoplasm
Fred Hutchinson Cancer Center
P3
BB
(66)
Dabrafenib
Cutaneous Melanoma
Immuneering Corporation
P3
BB
(66)
Dacarbazine
Hodgkin'S Lymphoma, Mixed Cellularity
National Cancer Institute (NCI)
P3
BB
(66)
Dacarbazine
Nodular Sclerosis Classical Hodgkin Lymphoma
National Cancer Institute (NCI)
P3
BB
(66)
Dacarbazine
Hodgkin'S Lymphoma, Lymphocytic Depletion
National Cancer Institute (NCI)
P3
BB
(66)
Dacarbazine
Hodgkin'S Lymphoma, Lymphocytic-Histiocytic Predominance
National Cancer Institute (NCI)
P3
BB
(66)
Dacarbazine
Uveal Melanoma
IDEAYA Biosciences
P3
BB
(66)
Dacarbazine
Soft Tissue Sarcoma
Institut Bergonié
P3
BB
(66)
Dalzanemdor
Huntington Disease
Supernus Pharmaceuticals, Inc.
P3
BB
(66)
Darolutamide
Prostate Adenocarcinoma
Region Stockholm
P3
BB
(66)
Dasatinib
Childhood Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
P3
BB
(66)
Daunomycin
Down Syndrome
National Hospital Organization Nagoya Medical Center
P3
BB
(66)
Daunomycin
Myeloid Sarcoma
Kura Oncology, Inc.
P3
BB
(66)
Showing 2476 to 2500 of 18,153 assets
Previous
Page 100 of 727
Next